Can botulinum toxin improve mood in depressed patients?

Expert Review of Neurotherapeutics

Volumn 12, Issue 9, 2012, Pages 1049-1051

  Han, Changsu ^a   Park, Geun Young ^b   Wang, Sheng Min ^b   Lee, Seung Yeop ^b   Lee, Soo Jung ^b   Bahk, Won Myong ^b   Pae, Chi Un ^b,c,d  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d The Catholic University of Korea   (South Korea)

Author keywords

botulinum toxin; depression; efficacy; facial expression; safety

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; PLACEBO;

ANGER; ANXIETY; COGNITION; DRUG EFFECT; ELECTROMYOGRAPHY; EMOTION; FACIAL EXPRESSION; FEAR; FEEDBACK SYSTEM; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SUICIDAL IDEATION;

EID: 84867298068     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.92     Document Type: Review

References (15)

1. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs, 25(2), 109-127 (2011).
2. Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs, 22(5), 367-388 (2008).
3. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9(6), 449-459 (2007).
4. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 60(11), 1439-1445 (2009).
5. Lin EH, Von Korff M, Ludman EJ et al. Enhancing adherence to prevent depression relapse in primary care. Gen. Hosp. Psychiatry 25(5), 303-310 (2003).
6. Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol. Surg. 32(5), 645-649; discussion 649 (2006).
7. Wollmer MA, de Boer C, Kalak N et al. Facing depression with botulinum toxin: a randomized controlled trial. J. Psychiatr. Res. 46(5), 574-581 (2012).
8. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62 (1960).
9. Honeck P, Weiss C, Sterry W, Rzany B; Gladys study group. Reproducibility of a four-point clinical severity score for glabellar frown lines. Br. J. Dermatol. 149(2), 306-310 (2003).
10. Martin JL, Martín-Sánchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur. Psychiatry 27(3), 147-155 (2012).
11. Fitzgerald PB, Daskalakis ZJ. The effects of repetitive transcranial magnetic stimulation in the treatment of depression. Expert Rev. Med. Devices 8(1), 85-95 (2011).
12. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am. J. Clin. Dermatol. 11(3), 183-199 (2010).
13. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J. Clin. Psychiatry 71(10), 1259-1272 (2010).
14. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 29(3), 259-266 (2009).
15. Heckmann M, Teichmann B, Schröder U, Sprengelmeyer R, Ceballos-Baumann AO. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J. Am. Acad. Dermatol. 49(2), 213-216 (2003).